VTVT · vTv Therapeutics Inc. Class A Common Stock
View on chartInsiders & Stakes
| PERELMAN RONALD O 10% Owner | ▼ Sell | Open Market | 36,519,212 Shares held | 12/20/2021 | View profile |
| Samsara BioCapital GP, LLC 10% Owner | ▼ Sell | Other | 206,784 Shares held | 3/5/2024 | View profile |
| BAKER BROS. ADVISORS LP Director | ▲ Buy | Grant | 135,946 Shares held | 9/3/2025 | View profile |
| Srinivas Akkaraju Director | ▲ Buy | Grant | 106,000 Shares held | 9/22/2025 | View profile |
| John A. Fry Director | ▲ Buy | Open Market | 61,000 Shares held | 11/29/2022 | View profile |
| Paul J. Sekhri Director | ▲ Buy | Open Market | 5,000 Shares held | 11/18/2024 | View profile |
Transaction History
| Srinivas Akkaraju | ▲ Buy | Grant | 106,000 | $1.6M | 9/22/2025 |
| BAKER BROS. ADVISORS LP | ▲ Buy | Grant | 4,308 | — | 9/3/2025 |
| BAKER BROS. ADVISORS LP | ▲ Buy | Grant | 46,692 | — | 9/3/2025 |
| Paul J. Sekhri | ▲ Buy | Open Market | 1,844 | $31K | 11/18/2024 |
| Paul J. Sekhri | ▲ Buy | Open Market | 1,378 | $23K | 11/15/2024 |
| Paul J. Sekhri | ▲ Buy | Open Market | 1,778 | $30K | 11/15/2024 |
| Samsara BioCapital GP, LLC | ▼ Sell | Other | 58,836 | — | 3/5/2024 |
| Srinivas Akkaraju | ▼ Sell | Other | 58,836 | — | 3/5/2024 |
| BAKER BROS. ADVISORS LP | ▼ Sell | Other | 4,776 | $0 | 3/5/2024 |
| BAKER BROS. ADVISORS LP | ▼ Sell | Other | 52,881 | $0 | 3/5/2024 |
| Srinivas Akkaraju | ▲ Buy | Grant | 224,732 | $2.7M | 2/27/2024 |
| John A. Fry | ▲ Buy | Open Market | 40,461 | $34K | 11/29/2022 |
| John A. Fry | ▲ Buy | Open Market | 20,539 | $17K | 11/28/2022 |
| PERELMAN RONALD O | ▼ Sell | Open Market | 87,000 | $100K | 12/20/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
VTVT Completes Phase 3 Cadisegliatin Trial Enrollment
vTv Therapeutics announced that enrollment for its phase 3 cadisegliatin trial in type 1 diabetes has been completed. The milestone moves the program closer to the next study stage and may influence future clinical and commercial outlook. The stock is currently trading near a long‑standing support level that has been tested many times.
VTVT Completes Phase 3 Cadisegliatin Trial Enrollment. vTv Therapeutics announced that enrollment for its phase 3 cadisegliatin trial in type 1 diabetes has been completed. The milestone moves the program closer to the next study stage and may influence future clinical and commercial outlook. The stock is currently trading near a long‑standing support level that has been tested many times.